The Patent Finder
BM

Beone Medicines I GmbH

First filing 2013
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as BeiGene Switzerland GmbH (to 2025)

83 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Dec 2031. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2031
Next term end
53
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Crystalline Form of (S)-7-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof US 10,927,117
Cited by 36 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2037.
Ends Aug 2037 · High confidence
Also notable
ANTI-PD1 Antibodies and Their Use as Therapeutics and Diagnostics US 8,735,553
The most cited patent in this portfolio, cited by 269 later US patents, top 5% of utility patents granted in 2014 in our data. Protection runs to 2033.
Ends Sep 2033 · High confidence
Also notable
SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS US 11,142,528
Cited by 34 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Ends Apr 2033 · Low confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 13, 2026
    The maintenance fee for ANTI-PD1 Antibodies and Their Use as Therapeutics and Diagnostics (US 11,673,951) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
  • 2 fees due Jan 16 to 18, 2027 · next Jan 16
  • 1 fee due Feb 15, 2027
    The maintenance fee for IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS (US 11,725,012) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
  • 3 fees due Apr 17 to 29, 2027 · next Apr 17
  • 1 fee due May 14, 2027
    The maintenance fee for CRYSTALLINE FORM OF (S)-7-(1-Acryloylpiperidin-4-YL)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-Carboxamide, PREPARATION, AND USES THEREOF (US 11,814,389) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
  • 4 fees due Jun 10 to 30, 2027 · next Jun 10
  • 2 fees due Jul 28 to 30, 2027 · next Jul 28
  • 6 fees due Aug 13 to 27, 2027 · next Aug 13
  • 2 fees due Sep 1 to 3, 2027 · next Sep 1
  • 1 fee due Oct 30, 2027
    The maintenance fee for CRYSTALLINE FORM OF (S)-7-(1-Acryloylpiperidin-4-YL)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-Carboxamide, PREPARATION, AND USES THEREOF (US 11,970,500) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
  • 2 fees due Nov 3 to 12, 2027 · next Nov 3

Which patents, and when each one lapses · Pro

Recent changes

  • Nov 3Assignment recorded on 1 record: Wang, Qiuwen and 2 others to Beone Medicines I GmbH Recorded Nov 3, 2026, executed Mar 18, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76609, frame 655.
  • 5 of the patents on this record were granted since Aug 23, 2026
  • 1 term has ended since Aug 23, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,260,440Fused Tetra or Penta-Cyclic Dihydrodiazepinocarbazolones as Parp Inhibitors
In force
 · High confidence
In forceHigh confidence
US 9,273,046Fused Tricyclic Compounds as Raf Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 9,328,111SUBSTITUTED CYCLOOCTA[5,6]PYRIDO[4,3,2-de]PHTHALAZINES AS PARP INHIBITORS
In force
 · High confidence
In forceHigh confidence
US 9,895,376Fused Tricyclic Compounds as Raf Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 10,501,467Fused Tetra or Penta-Cyclic Dihydrodiazepinocarbazolones as Parp Inhibitors
In force
 · High confidence
In forceHigh confidence
US 10,576,087Fused Tricyclic Compounds as Raf Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 9,447,106SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS
In force
 · High confidence
In forceHigh confidence
US 10,005,782Substituted Pyrazolo[1,5-a]pyrimidines as Bruton's Tyrosine Kinase Modulators
In force
 · Low confidence
In forceLow confidence
US 10,570,139SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS
In force
 · Low confidence
In forceLow confidence
US 11,142,528SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS
In force
 · Low confidence
In forceLow confidence
10 of 83 patents shown.
Pro members see all 83.
Pro members: see all 83 patents
Also on record, not counted in the 83: 2 patents ended · 119 applications pending · 4 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited